Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Radiofrequency Ablation With Chemotherapy Improves Progression-Free Survival in Unresectable Colorectal Cancer Liver Metastases: Presented at ESMO-GI By Jenny Powers BARCELONA, Spain -- July 1, 2009 -- The combination treatment of radiofrequency ablation (RFA) and standard chemotherapy prolongs progression-free survival (PFS) and decreases local disease recurrence, according to a study presented here at the 11th World Gastrointestinal Cancer Congress of the European Society for Medical Oncology (ESMO-GI). Theo J. Ruers, MD, Netherlands Cancer Institute, Amsterdam, The Netherlands, headed a team of researchers that sought to demonstrate the benefit of adding RFA of the tumour to chemotherapy in patients with unresectable colorectal cancer liver metastases. Unresectable tumours were defined as those having no surrounding disease-free margin. The primary endpoint was overall survival (OS) at 30 months, and secondary endpoints included safety, OS, and PFS. Patients with a maximum of 9 lesions and without extrahepatic disease were randomised to receive 6 months of chemotherapy consisting of oxaliplatin 85 mg/m2 and LV5FU2 plus, since October 2005, bevacizumab (n = 59) or RFA plus the same chemotherapy (n = 60). . Baseline characteristics of the patients were similar in both groups. In the RFA/chemotherapy arm, 30 patients (52.6%) received only RFA, and RFA was combined with resection in 27 patients (47.4%). The chemotherapy toxicity profiles were comparable between the study arms and consistent with those seen in previous trials. Postoperative complications were observed in 10 patients who received RFA (33%) and in 9 patients (33%) who underwent RFA plus resection. Three patients suffered cardiac arrest. Other complications observed in patients were haemorrhage (n = 2) and infection (n = 6). Three patients required reoperation, and 1 patient died after surgery. Minor complications of fever (n = 12) and fatigue (n = 6) were also observed. At 1 year, the PFS in the chemotherapy group was 39.35%, versus 60.06% in the RFA/chemotherapy group (P = .0267). At the interim analysis, the median PFS duration was 10 months in the chemotherapy arm and 16.8 months in the RFA/chemotherapy arm. Five patients had local recurrence at the RFA site, and 10% of the tumours converted to being resectable. The final analysis will be when the 30-month time point is reached. [Presentation title: Radiofrequency Ablation Combined With Chemotherapy for Unresectable CRC Liver Metastases: Interim Results of a Randomised Phase II Study (CLOCC) (EORTC-NCRI CCSG-ALM). Abstract 0022] E-mail this page to a friend or colleague! To print, use this version